Patent EP0045665A1 successfully refreshed from Google Patents.
EP0045665A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Enzyme inhibitors
Assignee: Hassle AB
•
Filing: 1981-08-05
•
Granted: —
•
Expires: 2001-08-05
Abstract
Abstract Preparation of renin inhibitors based on the structure of natural renin substrate at residues 6 to 13 from the amino terminal thereof, the inhibitors being polypeptide analogues having in particular an isosteric non-peptide link corresponding to the 10,11 peptide link of the substrate, and preparation of dipeptide analogues.
Inventors
- 👤 Michael Szelke
- 👤 David Michael Jones
- 👤 Alan Hallett
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 06:11
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/02; C07K5/0227; C07K5/04; C07K5/10; C07K5/1024; C07K7/00; C07K7/04; C07K7/14; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/86
Claims Analysis
Total Claims: 53
Claim 1
Independent Claim
521 words
A polypeptide analogue of the formula: where:- ' Pro, Phe and His may be in substituted form; X = H; or an acyl or other N-protecting group e.g. acetyl, pivaloyl, t-butyloxycarbonyl (Boc), benzoyl or lower alkyl (primarily C 1 -C 5 ); or an L- or D-amino- acyl residue, which may itself be N-protected similarly; Y = D- or L-His or other D- or L- basic or aromatic amino-acyl residue, or is absent; "reduced" isostere bond or "keto" isostere bond or "hydroxy" isostere bond or "hydrocarbon" isostere bond where the configuration at asymmetric centres * is either R or S, where in VIII the hydroxy group may be present as such or protected in ether -OR 4 or ester form where R 4 is as given under W below and where R 1 and R 2 , the same or different = i Pro (isopropyl), i Bu (isobutyl), Bzl (benzyl) or other lipophilic or aromatic amino-acid side chain R 3 = -H; lower alkyl (C 1 -C 5 ); or -SO 2 Ph, -SO 2 C 6 H 4 CH 3 (p), Boc, formyl or other N-protecting group; B= D- or L- Val or Ile or other D- or L- lipophilic amino-acyl residue; Z = D- or L- Tyr, Phe, His or other L- or D-aromatic amino-acyl residue; and W = -OH as such or in protected ester form as -OR 4 where R4 = lower alkyl primarily C 1 -C 5 and particularly t Bu, or cycloalkyl primarily C 3 -C 7 , or Bzl, or other ester forming group; or -NH 2 as such or in protected amide form as -NHR 5 or -N(R 5 ) 2 (where R 5 = an N-protecting or other substituent group e.g. lower alkyl as for R 4 and (R 5 ) 2 = two such or e.g, cyclo- alkyl, primarily C 3 -C 7 ) or as -NH-(CH 2 ) n -Q or -NR -(CH 2 ) n -Q (where n = 2 to 6 and Q = NH 2 or and wherein any of the hydrogens attached to nitrogen may be substituted by R 5 or (R 5 ) 2 ); an L- or D-serine or lysine, arginine or other basic amino-acyl residue as such or in amide form, substituted amide form or ester form e.g. containing a group or groups as given for R 4 and R 5 above as the case may be; or an amino alcohol residue derived therefrom as such or protected in ester or ether form e.g. containing a group as given for R 4 above or L- or D-Z + W = an alcohol derived from/Tyr, Phe, His or other L-or D- aromatic amino-acyl residue as such or protected in ester or ether form as above; such polypeptide being in the above form or modified by isosteric replacement of one or more remaining peptide bonds by reduced,-CH 2 -NH-, keto, hydroxy, -CH(OH)-CH 2 -,or hydrocarbon, -CH 2 -CH 2 - isosteric links and further being in free form or in protected form at one or more remaining peptide, carboxyl, amino, hydroxy or other reactive groups.
Claim 2
Dependent Claim
521 words
A polypeptide analogue of the formula: where:- ' Pro, Phe and His may be in substituted form; X = H; or an acyl or other N-protecting group e.g. acetyl, pivaloyl, t-butyloxycarbonyl (Boc), benzoyl or lower alkyl (primarily C 1 -C 5 ); or an L- or D-amino- acyl residue, which may itself be N-protected similarly; Y = D- or L-His or other D- or L- basic or aromatic amino-acyl residue, or is absent; "reduced" isostere bond or "keto" isostere bond or "hydroxy" isostere bond or "hydrocarbon" isostere bond where the configuration at asymmetric centres * is either R or S, where in VIII the hydroxy group may be present as such or protected in ether -OR 4 or ester form where R 4 is as given under W below and where R 1 and R 2 , the same or different = i Pro (isopropyl), i Bu (isobutyl), Bzl (benzyl) or other lipophilic or aromatic amino-acid side chain R 3 = -H; lower alkyl (C 1 -C 5 ); or -SO 2 Ph, -SO 2 C 6 H 4 CH 3 (p), Boc, formyl or other N-protecting group; B= D- or L- Val or Ile or other D- or L- lipophilic amino-acyl residue; Z = D- or L- Tyr, Phe, His or other L- or D-aromatic amino-acyl residue; and W = -OH as such or in protected ester form as -OR 4 where R4 = lower alkyl primarily C 1 -C 5 and particularly t Bu, or cycloalkyl primarily C 3 -C 7 , or Bzl, or other ester forming group; or -NH 2 as such or in protected amide form as -NHR 5 or -N(R 5 ) 2 (where R 5 = an N-protecting or other substituent group e.g. lower alkyl as for R 4 and (R 5 ) 2 = two such or e.g, cyclo- alkyl, primarily C 3 -C 7 ) or as -NH-(CH 2 ) n -Q or -NR -(CH 2 ) n -Q (where n = 2 to 6 and Q = NH 2 or and wherein any of the hydrogens attached to nitrogen may be substituted by R 5 or (R 5 ) 2 ); an L- or D-serine or lysine, arginine or other basic amino-acyl residue as such or in amide form, substituted amide form or ester form e.g. containing a group or groups as given for R 4 and R 5 above as the case may be; or an amino alcohol residue derived therefrom as such or protected in ester or ether form e.g. containing a group as given for R 4 above or L- or D-Z + W = an alcohol derived from/Tyr, Phe, His or other L-or D- aromatic amino-acyl residue as such or protected in ester or ether form as above; such polypeptide being in the above form or modified by isosteric replacement of one or more remaining peptide bonds by reduced,-CH 2 -NH-, keto, hydroxy, -CH(OH)-CH 2 -,or hydrocarbon, -CH 2 -CH 2 - isosteric links and further being in free form or in protected form at one or more remaining peptide, carboxyl, amino, hydroxy or other reactive groups.
Claim 3
Dependent Claim
277 words
A polypeptide analogue, according to claim 1, of the formula: where X, Y, Pro, Phe and His are as in claim 1 A is as in claim 1 except that R 1 and R 2 , the same or different = Bu (isobutyl) or Bzl (benzyl) or other lipophilic or aromatic amino-acid side chain R 3 = -H; or -S0 2 Ph, -SO 2 C 6 H 4 CH 3 (p), Boc, formyl or other N-protecting group Z = Tyr, Phe or other L- or D-aromatic amino-acyl residue; W = -OH as such or in protected ester form as -OR 4 where R 4 = lower alkyl (primarily C 1 -C 5 and particularly t Bu), or Bzl, or other ester forming group ; or -NH 2 as such or in protected amide form as -NHR S or -N(R 5 ) 2 (R 5 = an N-protecting group e.g. lower alkyl as for R 4 ; (R 5 ) 2 = two such or e.g. cyclo-alkyl, primarily C 3 -C 7 ) or an L- or D- amino-acyl residue e.g. a serine or basic amino-acyl residue as such or in amide form or in protected amide or ester form e.g. containing a group or groups as given for R 4 and R 5 above as the case may be; or an amino acid alcohol residue derived therefrom as such or protected in ester or ether form e.g. containing a group as given for R 4 above or Z + W = an alcohol derived from Tyr or Phe or other L-or D- aromatic amino acyl residue as such or protected in ester or ether form as above.
Claim 4
Dependent Claim
119 words
A polypeptide analogue, according to claim 1, of the formula: where X, Y, Pro, Phe and His are as in claim 1 A is as in claim 1 except that R 1 = i Bu (isobutyl) or Bzl (benzyl) or other lipophilic or aromatic amino-acid side chain R 2 = i Pr (isopropyl), and R 3 = -H; or -S0 2 Ph, -SO 2 C 6 H 4 CH 3 (p), Boc, formyl or other N-protecting group Z is as in claim 1 W is as in claim 2 or Z + W = an alcohol derived from the aromatic residues specified for Z in claim 1, as such or protected in ester or ether form as specified therein.
Claim 5
Dependent Claim
29 words
A polypeptide according to any one of claims 1 to 3, modified by isosteric replacement, as set out therein, at one or both of the Pro-Phe or Phe-His links.
Claim 6
Dependent Claim
26 words
A polypeptide according to any one of claims 1 to 4 wherein the isosteric replacement at at least the 10,11 position is of the "reduced" kind.
Claim 7
Dependent Claim
26 words
A polypeptide according to any one of claims 1 to 4 wherein the isosteric replacement at at least the 10,11 position is of the "hydroxy" kind.
Claim 8
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Leu-Val-Tyr-OH.
Claim 9
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Leu-Val-Tyr-OH.
Claim 10
Dependent Claim
3 words
The compound: H-Pro-Phe-His-Leu-reduced-Leu-Val-Tyr-OH.
Claim 11
Dependent Claim
3 words
The compound: H-Pro-Phe-His-Leu-reduced-Leu-Val-Tyr-OH.
Claim 12
Dependent Claim
6 words
The compound: H-His-Pro-Phe-His-Leu-reduced (S0 2 Ph)-Leu-Val-Tyr-OH.
Claim 13
Dependent Claim
6 words
The compound: H-His-Pro-Phe-His-Leu-reduced (S0 2 Ph)-Leu-Val-Tyr-OH.
Claim 14
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Leu-reduced-Leu-Val-Tyr-OH.
Claim 15
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Leu-reduced-Leu-Val-Tyr-OH.
Claim 16
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Val-Ile-His-OH.
Claim 17
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Val-Ile-His-OH.
Claim 18
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Phe-reduced-Phe-Val-Tyr-OH.
Claim 19
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Phe-reduced-Phe-Val-Tyr-OH.
Claim 20
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Leu-reduced-Phe-Val-Tyr-OH.
Claim 21
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Leu-reduced-Phe-Val-Tyr-OH.
Claim 22
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Phe-reduced-Phe-Val-Tyr-OH.
Claim 23
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Phe-reduced-Phe-Val-Tyr-OH.
Claim 24
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Phe-Val-Tyr-OH.
Claim 25
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Phe-Val-Tyr-OH.
Claim 26
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Val-Ile-Tyr-OH.
Claim 27
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Val-Ile-Tyr-OH.
Claim 28
Dependent Claim
3 words
The compound: H-Pro-His-Pro-Phe-His-Phe-reduced-Phe-Val-Tyr-Lys-OH.
Claim 29
Dependent Claim
3 words
The compound: H-Pro-His-Pro-Phe-His-Phe-reduced-Phe-Val-Tyr-Lys-OH.
Claim 30
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Val-Val-Tyr-OH.
Claim 31
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-reduced-Val-Val-Tyr-OH.
Claim 32
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-hydroxy-Leu-Val-Tyr-OH.
Claim 33
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-hydroxy-Leu-Val-Tyr-OH.
Claim 34
Dependent Claim
5 words
The compound: H-Pro-Phe-His-Leu-hydroxy - Leu-Val-Tyr-OH.
Claim 35
Dependent Claim
5 words
The compound: H-Pro-Phe-His-Leu-hydroxy - Leu-Val-Tyr-OH.
Claim 36
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Leu-hydroxy-Leu-Val-Tyr-OH.
Claim 37
Dependent Claim
3 words
The compound: H-DHis-Pro-Phe-His-Leu-hydroxy-Leu-Val-Tyr-OH.
Claim 38
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-hydroxy-Val-Ile-His-OH.
Claim 39
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-hydroxy-Val-Ile-His-OH.
Claim 40
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-keto-Val-Ile-His-OH.
Claim 41
Dependent Claim
3 words
The compound: H-His-Pro-Phe-His-Leu-keto-Val-Ile-His-OH.
Claim 42
Dependent Claim
74 words
.A method of making a hydroxy or keto isostere of a dipeptide wherein a derivative of a halohydrin preferably a bromohydrin or haloketone preferably a bromoketone wherein R 6 is an amino acid side chain and the NH 2 and OH groups are in protected form is alkylated to give the desired isostere p 6 On as such or in protected form, R 7 being the same or a different amino acid side chain.
Claim 43
Dependent Claim
74 words
.A method of making a hydroxy or keto isostere of a dipeptide wherein a derivative of a halohydrin preferably a bromohydrin or haloketone preferably a bromoketone wherein R 6 is an amino acid side chain and the NH 2 and OH groups are in protected form is alkylated to give the desired isostere p 6 On as such or in protected form, R 7 being the same or a different amino acid side chain.
Claim 44
Dependent Claim
32 words
A method according to claim 24 wherein the alkylation procedure is by reaction with an alkali metal carboxylic acid derivative preferably a lithium derivative where R 7 is as in claim 24.
Claim 45
Dependent Claim
70 words
A method according to claim 25 wherein the alkylation procedure is by reaction with an alkali metal malonic ester derivative preferably a sodium derivative where R 8 is an esterifying group and a halide preferably an iodide where R is as in claim 24 to give intermediate in protected form which intermediate is then decarboxylated and if desired deprotected to give the desired isostere as such or in protected form.
Claim 46
Independent Claim
43 words
A method of making a keto isostere of a dipeptide wherein a hydroxy isostere is made by the method of any of claims 24 to 26 and the -CH(OH)- group is oxidised to give the desired isostere as such or in protected form.
Claim 47
Dependent Claim
54 words
The method of any of claims 24 to 27 when applied to the production of a hydroxy dipeptide isostere of the formula or the corresponding keto isostere , where the significance of *, X 1 and W 1 is as in claim 1 except that X 1 and W 1 do not represent amino-acyl.
Claim 48
Dependent Claim
34 words
A hydroxy or keto isostere of a dipeptide when made by the method of any of claims 24 to 28, as such or in the form of a higher polypeptide analogue made using it.
Claim 49
Dependent Claim
56 words
In a diagnostic test for high-renin states, blood pressure falling most when renin is high, and as a surgical prognostic test for reno-vascular hypertension (renal artery stenosis), the administration of a polypeptide analogue according to any one of claims 1 to 23 followed by monitoring of blood pressure, and such polypeptide analogues when for such use.
Claim 50
Dependent Claim
50 words
In the long and short term treatment of heart failure and all forms of hypertension particularly those associated with high serum renin levels, the administration of a renin-inhibiting amount of a polypeptide analogue according to any one of claims 1 to 23, and such polypeptide analogues when for such use.
Claim 51
Dependent Claim
24 words
Administration according to claim 30 or 31, of 0.001 to 10 mg/kg body weight daily, preferably 0.01 to 1.0 mg, of the polypeptide analogue.
Claim 52
Dependent Claim
26 words
A polypeptide analogue according to any one of claims 1 to 23, when in the form of a composition with a pharmaceutically acceptable diluent or carrier.
Claim 53
Dependent Claim
22 words
The composition of claim 33, in unit dosage form containing the amounts of analogue set out in claim 32 or sub-multiple thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.